Saturday, July 11, 2026

pharma · Vestibular Disorder

Eye & ENT

Eye & ENT drug portfolio — 1 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.

CN HQ
NMPA registrant Type
Company details
Status
Public
HQ
CN
Programs
1
Drugs
1
Patents
0
Intelligence · Drug Pipeline

Eye & ENT pipeline

Portfolio lens on 1 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.

Eye & ENT drug portfolio — 1 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.

Drug portfolio

1 compounds
  1. Development asset linked to Eye & ENT in public FDA and regional records.